Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR.

• Tác giả: H Ardeschir Ghofrani, David B Badesch, Alexandra G Cornell, Janethe de Oliveira Pena, J Simon R Gibbs, Mardi Gomberg-Maitland, Ekkehard Grünig, Marius M Hoeper, Marc Humbert, Amy O Johnson-Levonas, Grzegorz Kopeć, Vallerie V McLaughlin, Gisela Meyer, Karen M Olsson, Loïc Perchenet, Ioana R Preston, Stephan Rosenkranz, Rogerio Souza, James Strait, Aaron B Waxman, Aiwen Xing
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation , 2025
• Bộ sưu tập: NCBI
• ID: 720431

Tóm tắt

 BACKGROUND: This analysis examined the effects of the activin signaling inhibitor, sotatercept, in pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI). METHODS: Pooled data from PULSAR (N = 106
  NCT03496207) and STELLAR (N = 323
  NCT04576988) were analyzed using 2 different CI thresholds, <
 2.0 and ≥2.0 liter/min/m RESULTS: Of 429 participants, 51 had CI <
 2.0 and 378 ≥2.0 liter/min/m CONCLUSIONS: Sotatercept demonstrated consistent efficacy and safety across CI subgroups, supporting its use in PAH patients irrespective of baseline cardiac hemodynamics.